AusperBio Completes Patient Enrollment in Phase III AUSHINE Study of AHB-137 for Chronic Hepatitis B
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company developing targeted oligonucleotide therapies for functional cure of chronic ...
Vir Biotechnology is handing off certain commercial rights for its hepatitis D program to European specialty pharma Norgine ...
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it will be presenting new data from its ongoing Phase 2 SOLSTICE and MARCH trials evaluating the potential ...
First patient enrolled in ECLIPSE 1 Phase 3 clinical trial evaluating combination of tobevibart and elebsiran for chronic suppressive treatment ECLIPSE program designed to enable regulatory ...
Pharmaceutical Technology on MSN
Mirum to buy Bluejay for up to $820m in rare liver disease push
The deal gives Mirum access to Bluejay’s monoclonal antibody brelovitug, which is currently in Phase III trials.
A 98% Sustained Virologic Response at Week 4 (SVR4) Post-Treatment Observed in Initial Data From 52 Patients in Lead-In Cohort in Phase 2 HCV Study Phase 3 SUNRISE-3 Enrollment Surpassed 650 Patients ...
US rare disease drug developer Mirum Pharmaceuticals today announced its entry into a definitive agreement to acquire Bluejay ...
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 ...
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational program is ...
Mirum Pharmaceuticals Inc. has agreed to acquire Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback